Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Yahoo! Finance
TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target. Positive considerations for FDMT and the group in 2026 included the biotech industry's solid fundamentals, the undervaluation of several companies, anticipated tailwinds from mergers and acquisitions, and a decreased emphasis on medicine prices. Separately, on January 7, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) provided a 2026 corporate update. The 4FRONT Phase 3 investigations of 4D-150 in Wet AMD involved 480 patients in each phase; 381 participants have already been randomized for 4FRONT-1, and global enrollment for 4FRONT-2 is anticipated to be completed by H2 2026. A global Phase 3 trial for diabetic macular edema is scheduled for Q3, and 2-year SPECTRA Phase 1/2 results are anticipated in H2 2026. The second half of the year is also expected to see updates on the Phase 2 4D-710 program for cystic fibrosis. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.MarketBeat
- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- 4DMT Provides Company Update and Anticipated Development Milestones for 2026GlobeNewswire
- Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]Yahoo! Finance
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 1/26/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 3
- FDMT's page on the SEC website